Business Wire

Amazon study reveals most European employees favour on-the-job skills training or apprenticeships over university degrees for a successful career start

Share

More than half of European workers (54%) believe that on-the-job-skills training or apprenticeships are more valuable for preparing people for work today than traditional university degrees, a new European career insights and workplace trends study commissioned by Amazon has found. In fact, the study found that just under three quarters (73%) of workers feel there needs to be a wider range of apprenticeship or internship opportunities available to young people.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613014196/en/

The Amazon Future of Work & Career Development European study, conducted by Ipsos, also found that a majority of European employees* (89%) think it’s important to learn a new skill to improve or change their career path, even more so than receiving a promotion (73%). Alongside factors such as pay/salary (94%) and office/worksite location or flexible/hybrid or remote working (93%), 91% of adults say on the job training or career development training is essential or important when looking for a new job or role, and that training programmes offered by a potential employer are more important than company culture (78%). One potential reason is that many workers in the study said it would make them feel motivated (39%), encouraged (32%), valued (31%) or supported (30%) to work for a company that provides access to career development training. Additionally, almost one in five workers in Europe (19%) admit they couldn’t afford to pay for training.

Amazon has long adapted to the ever-changing career and education landscape, investing more than €100 million in training programmes in Europe since it launched its Career Choice programme in the region in 2014. The programme provides 95% of pre-paid tuition, up to €8,000 over four years, for nationally recognised courses from more than 85 schools throughout Europe. It offers various training opportunities in a range of popular, in-demand job fields, from tech and sustainability to business administration and logistics, for Amazon’s hourly and salaried workers across the region.

To mark the ten-year anniversary of Career Choice in Europe, Amazon plans to invest €40 million in 2024 and to add more than 25 new programmes across five countries in Europe this year to support current and future job needs for the thousands of employees who participate in Career Choice. Currently, Amazon employees in Europe have access to over a hundred different programmes to help them maximise their potential within the company or outside of Amazon. Some of the new courses added in 2024 include Cloud Support, Cyber Security, Information Security, Web and Graphic Design, Mechatronics, Procurement Logistics, and Big Data, Virtualisation, and Machine Learning.

Since its launch ten years ago, more than 40,000 Amazon employees across Europe** have participated in the programme. While some employees leave Amazon to pursue other career opportunities with their newly acquired skills and certifications from Career Choice, thousands have stayed and transitioned into new roles. The popularity of the programme continues to increase, with about one in ten of all eligible employees in Europe participating in Career Choice in 2023. Popular areas of study vary from technology and sustainability, to mechanical and industrial systems, transportation and logistics, and administration and business studies.

“I attribute a lot of my growth at Amazon to Career Choice,” said Mo Abdullahi, Senior Operations Manager and Career Choice participant number four in the UK from 2014. “It gave me an opportunity to learn more about the role that I wanted and helped me with obtaining the qualifications that I needed. I'm still super surprised of my journey and growth through Amazon. If I look back ten years ago and starting as a temporary worker, I certainly wouldn't have assumed that I would be at the level I am right now and with the responsibility I have now. It’s been an incredible journey.”

When it comes to jobs in the future, the study shows that training will need to play a key role in alleviating worker concerns, as 32% of European workers are worried they won’t have the training and skills to be relevant in their job in the coming years. In fact, two-thirds of European workers (67%) believe that people in the workforce today will need to continue to retrain and update their skills to continue working in the future. However, only 15% of employees say they have access to training to help them change their career path, and over one in five (22%) employees say they don’t have any access to training with their current employer.

“The latest research and the growth of our Career Choice programme over the past ten years clearly demonstrates the strong desire for workers across the Europe to develop their careers through relevant and accessible skills training programmes,” said Robert Marhan, Global Operations Vice President of People Experience & Technology (PXT). “Amazon is proud to celebrate the tenth anniversary of the Career Choice skills training programme in Europe and to expand the course options available, so that thousands of employees across Europe can advance their skills and take on new career opportunities both at Amazon and beyond.”

The Career Choice programme is currently available to Amazon employees in Australia, Canada, Costa Rica, Czech Republic, France, Germany, Ireland, Italy, Poland, Slovakia, South Africa, Spain, the U.S., and the UK. It has a rigorous selection process for third-party partner educators, choosing partners that are focused on helping employees through their education programmes, assisting them with job placements, and overall offering education that leads to career success.

To learn more about the Career Choice programme, visit Amazon Career Choice https://www.aboutamazon.eu/news/tag/working-at-amazon/career-choice

Sources:

*The research was carried out by Ipsos UK on behalf of Amazon. Ipsos UK interviewed a representative quota sample of 16,482 adults using its online omnibus, and within that a sample of 9,686 employees. Fieldwork was carried out in 8 markets across Europe, including Spain, Germany, UK, France, Italy, Slovakia, Czech Republic, Poland. The sample achieved is representative of the population aged 16-75 in all markets except Czech Republic and Slovakia, where the participants were aged 16-65. Interlocking quotas were set on Age within Gender, and on Region and Working status. The data has been weighted to the known offline population proportions for interlocking cells of gender within age and working status, as well as region and education to reflect the adult population of each market. A country average weight was also applied. Fieldwork was carried out between the 26th April and 27th May 2024. This research was conducted as part of a global study across Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Africa, Slovakia, Spain, and the UK.

**Amazon Career Choice participation data collected in Europe between 2014-24.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613014196/en/

Contacts

Louise Thach thachl@amazon.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye